Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to infection. Neurotensin (NT) is a 13-amino-acid peptide that, among its multiple effects, induces hypotension. We find that intraperitoneal and plasma concentrations of NT are increased in mice after severe cecal ligation and puncture (CLP), a model of sepsis, and that mice treated with a pharmacological antagonist of NT, or NT-deficient mice, show reduced mortality during severe CLP. In mice, mast cells can degrade NT and reduce NT-induced hypotension and CLP-associated mortality, and optimal expression of these effects requires mast cell expression of neurotensin receptor 1 and neurolysin. These findings show that NT contributes to sepsis-related mortality in mice during severe CLP and that mast cells can lower NT concentrations, and suggest that mast cell-dependent reduction in NT levels contributes to the ability of mast cells to enhance survival after CLP.
Sepsis is the most common cause of death in intensive care units in the United States 1 . The host response to sepsis is complex, yet the factors responsible for the pathology and death associated with sepsis are not fully understood [1] [2] [3] [4] [5] . Moreover, there is considerable interest in identifying additional biomarkers and therapeutic targets in this disorder 6, 7 .
NT is a tridecapeptide that exerts potent effects in the central nervous system and the periphery 8 . There are two G protein-coupled receptors for NT, the high-affinity receptor, Ntsr1, and the low-affinity receptor, Ntsr2 (refs. 9,10) . Ntsr3, originally identified as the intracellular sorting protein sortilin 11 , is a non-G protein-coupled receptor that binds NT with high affinity but is of unknown function 8 . Although NT can induce hypotension 12 , a common problem in sepsis 13 , the potential contributions of NT to the pathology of sepsis have not previously been investigated.
We provide pharmacological and genetic evidence that NT can contribute to mortality in mice subjected to severe cecal ligation and puncture (CLP), a model of acute septic peritonitis 14 . Mast cells (MCs) can be activated by several mechanisms in CLP and can promote survival in this setting [15] [16] [17] , and both TNF [18] [19] [20] , of mouse MC protease-6 (mMCP-6) 21 have been reported to reduce mortality in CLP 19, 20 or other models of infection 18, 21 .
Because certain MC-derived proteases can degrade NT 22, 23 , we hypothesized that an additional mechanism by which MCs can promote survival in CLP is by reducing levels of NT. We now report evidence that strongly supports that hypothesis.
RESULTS
NT contributes to mortality in sepsis NT-deficient (Nts À/À ) mice resemble wild-type mice in general appearance, gross anatomy, body weight, reproduction and overt behavior 24 . Nts +/+ and Nts À/À mice were similar in percentage of MCs in the peritoneal cavity (2.1% ± 0.1% or 1.7% ± 0.2% of cells in peritoneal lavage fluid), distribution of MCs in the mesentery (Supplementary Fig. 1 online) , and survival after moderate CLP (P ¼ 0.74; Fig. 1a ). However, after severe CLP, Nts À/À mice showed significantly higher systemic blood pressure ( Supplementary Fig. 2a online) and enhanced survival (56% versus 25% survival at 1 week after CLP, P o 0.05) (Fig. 1b) compared to Nts +/+ mice.
We detected higher amounts of NT in the peritoneal cavity and plasma of C57BL/6 mice in severe versus moderate CLP (Fig. 1c,d ). As previously reported 17 , endothelin-1 expression (ET-1) was also increased in the peritoneal fluid of C57BL/6 mice after CLP (87.2 ± 13.2 fmol/peritoneum (n ¼ 10) versus 18.0 ± 1.0 fmol/peritoneum (n ¼ 4) 18 h after severe CLP versus sham operation, respectively, P o 0.002). Compared to wild-type mice, survival after severe CLP was significantly enhanced in Ntsr1 À/À but not Ntsr2 À/À mice ( Supplementary Fig. 2b ), indicating that Ntsr1 is more important than Ntsr2 in the pathways by which NT promotes pathology in this setting.
Mast cells regulate NT levels during sepsis
MCs can promote survival in mice subjected to CLP 19 , and there is evidence that MC activation by ET-1 can contribute to both MCdependent reduction in ET-1 in the peritoneal cavity and enhanced survival in CLP 17 . Certain MC populations can also be activated by NT in vitro 25, 26 . Amounts of NT in the peritoneal cavity were significantly higher in genetically MC-deficient Kit W/W-v mice versus congenic normal (Kit +/+ ) mice 24-28 h after moderate CLP (Fig. 2a) .
To assess the extent to which this difference reflected the MC deficiency of Kit W/W-v mice, as opposed to other consequences of their c-kit mutations, we analyzed Kit W/W-v mice selectively engrafted intraperitoneally with Kit +/+ bone marrow-derived cultured MCs (BMCMCs) (Kit +/+ BMCMCs-Kit W/W-v mice) 27 . Amounts of NT in the peritoneal cavity after moderate CLP in Kit +/+ BMCMCsKit W/W-v mice were very similar to those in Kit +/+ mice (Fig. 2a) .
Treatment with SR142948A, a nonselective antagonist of Ntsr1 and Ntsr2 (ref. 28) , significantly improved survival in Kit W/W-v mice subjected to moderate CLP (50% survival 1 week after CLP versus all vehicle-treated mice dead by 48 h, P o 0.02; Fig. 2b ). Survival of Kit +/+ mice subjected to moderate CLP was not significantly influenced by treatment with SR142948A (P ¼ 0.15; Fig. 2c ). However, SR142948A treatment significantly enhanced survival of Kit +/+ mice after severe CLP (26% at 1 week versus 6% in vehicle-treated mice, P o 0.04; Fig. 2d ). As in C57BL/6 (Nts +/+ ) mice (Fig. 1c,d ), NT levels were significantly higher in the peritoneal cavity and plasma of WBB6F 1 -Kit +/+ mice that were subjected to severe as opposed to moderate CLP (Fig. 2e,f) .
Taken together with the enhanced survival of Nts À/À (Fig. 1b) or Ntsr1 À/À ( Supplementary Fig. 2b) the mortality associated with severe CLP and that MCs can regulate NT concentrations in the peritoneal cavity after CLP.
Mast cells degrade NT and prevent NT-induced hypotension
Rat peritoneal MCs (PMCs) can degrade NT in vitro 22 . In accordance with that result, peritoneal lavage cells (PLCs) of Kit +/+ , but not MCdeficient, Kit W/W-v mice were able to reduce concentrations of NT in vitro ( Supplementary Fig. 3a online). To assess whether MCs can reduce levels of NT in vivo in mice not subjected to CLP, we administered NT intraperitoneally (6 nmol in 300 ml saline), and then measured mean arterial blood pressure (MAP). NT induced more significant reductions in MAP in Kit W/W-v mice than in Kit +/+ or Kit +/+ BMCMCs-Kit W/W-v mice (Fig. 3a) . Moreover, 30 min after NT injection, amounts of NT were significantly higher in the peritoneal cavities of Kit W/W-v mice than in Kit +/+ or Kit +/+ BMCMCs-Kit W/W-v mice (Fig. 3b) . Thus, MCs can reduce levels of NT in vitro and in vivo and can also limit the extent of NT-induced hypotension in vivo.
Mast cells express neurolysin
Using inhibitors of various proteases that can degrade NT 22, 23, 29 , we found that NT degradation by PLCs was significantly inhibited by the mouse MC carboxypeptidase A (mMC-CPA) inhibitor potato carboxypeptidase inhibitor (PCI) 26 and by the neurolysin (NLN) inhibitor phosphodiepryl 03 (p03) 30 ( Supplementary Fig. 3b ).
Neither the chymase inhibitor chymostatin (Chym) 31 nor the inhibitor of thimet oligopeptidase, CFp-Ala-Ala-Phe-pAB (CFp) 32 , significantly influenced NT degradation by PLCs ( Supplementary  Fig. 3b ). Human skin chymase can degrade NT 23 . However, NT was degraded to the same extent by PLCs of wild-type control mice and mouse MC protease-4 (mMCP-4)-deficient (Mcpt4 -/-) mice, which lack mMCP-4, the major protease of mouse PMCs with chymotryptic activity 33 ( Supplementary Fig. 3c ). NLN, a zinc metalloendopeptidase expressed in tissues such as kidney, ileum and testis 34 , has not been previously described in MCs. PLCs that contained MCs showed significantly higher amounts of NLN activity than did PLCs that virtually lacked MCs (Supplementary Fig. 3d ). Mouse MCs contained NLN mRNA and protein ( Supplementary Fig. 4a ,b online), and active NLN was present in both the membrane and cytosol fractions of such cells ( Fig. 4a and Supplementary Fig. 4c ). Moreover, either membrane or cytosol preparations of mouse BMCMCs degraded NT, an ability that was almost completely inhibited by the NLN inhibitor Pro-Ile (10 mM; Fig. 4b ) 35 .
PCI may inhibit NT degradation by rat MCs in part by interfering with the binding of NT to MCs, thus reducing MC degranulation 26 . We therefore also used a nonpharmacological approach to assess the extent to which MC-derived mMC-CPA or NLN can degrade NT Figure 3 MCs reduce peritoneal NT concentrations and NT-induced hypotension. (a,b) Changes in MAP versus baseline levels (baseline ¼ 0, measured 3 min after injection of 300 ml saline, intraperitoneal, i.p.) at various times after injection of NT (6 nmol in 300 ml saline, intraperitoneal) (a) and amounts of NT in the peritoneal fluids of these mice at 30 min after injection of NT (b) in wild-type ( Results are expressed as the percentage of NT remaining in the samples compared to that in samples of NT incubated in vehicle alone at 37 1C (n ¼ 9 per group, data were pooled from three independent experiments that gave similar results). (e) Changes in MAP versus baseline levels (baseline ¼ 0, measured 3 min after injection of 300 ml saline, intraperitoneal) at various times after injection of NT (6 nmol in 300 ml saline, intraperitoneal) Fig. 5a ,b online). By contrast, infection of BMCMCs with mMC-CPA or NLN shRNA did not detectably reduce expression of NLN or mMC-CPA, respectively ( Supplementary Fig. 5c,d ). In agreement with results reported for PMCs from mMC-CPA-deficient mice 36 , the reduced abundance of mMC-CPA was associated with reduced expression of mMCP-5, but not mMCP-4, protein, whereas no effects on these proteases were observed in MCs with reduced levels of NLN ( Supplementary Fig. 5e ).
MC degranulation results in secretion of mMC-CPA and other MC mediators, and either mMC-CPA-or NLN-shRNA-transduced BMCMCs showed significantly reduced ability to degrade NT after induction of BMCMC degranulation with A23187 (5 mM; Fig. 4c,d) . Notably, BMCMCs transduced with shRNAs for NLN or mMC-CPA degranulated to the same extent as empty vector-treated cells upon FceRI cross-linking ( Supplementary Fig. 5f ), indicating that these treatments did not globally reduce MC secretory function. These results indicate that either mMC-CPA or NLN can contribute to the ability of MCs to degrade NT when MCs are induced to degranulate in vitro.
Role of mast cell NLN in reducing NT-induced hypotension To assess the extent to which NLN or mMC-CPA can contribute to MC-dependent reduction of NT-induced hypotension, Kit W/W-v mice were engrafted with BMCMCs transduced with shRNA to silence either NLN or mMC-CPA. Compared to results in control mice, intraperitoneal injection of NT significantly reduced MAP in NLNshRNA BMCMCs-Kit W/W-v mice but not in mMC-CPA-shRNA BMCMCs-Kit W/W-v mice (Fig. 4e) . The percentage of PMCs among total cells in the peritoneal cavity were similar in Kit W/W-v mice engrafted with MCs transduced with either empty vector, NLN-shRNA or mMC-CPA-shRNA (2.8% ± 0.1%, 3.5% ± 0.8% or 4.0% ± 0.9%, respectively), as was the distribution of MCs in the mesentery ( Supplementary Fig. 6 online) . These results indicate that MC-derived NLN is more important than mMC-CPA in protecting mice from hypotension induced by intraperitoneal injection of NT in vivo.
Mast cells can degrade NT without extensive degranulation
Notably, PMCs in Kit +/+ mice showed only moderate degranulation at 30 min after intraperitoneal injection of NT, especially when compared with PMCs in mice injected intraperitoneally with ET-1 (Fig. 5a ). Moreover, NT had little or no ability to induce PMCs to release serotonin or mMC-CPA in vitro (Fig. 5b,c) . Also, inhibition of PMC degranulation with the membrane-permeable Ca 2+ chelator BAPTA-AM (50 mM, 30 min) 17 , which markedly inhibited ET-1-induced PMC serotonin release (Fig. 5b) , did not reduce the ability of PMCs to degrade NT in vitro (Fig. 5d) . These results indicate that PMCs can degrade NT even when such PMCs have not been induced to undergo extensive degranulation.
Role of mast cell Ntsr1
To assess the potential involvement of NT receptors in MC degradation of NT, we assessed the NT degradation ability of PLCs isolated from Ntsr1 À/À and Ntsr2 À/À mice. NT degradation was significantly impaired in Ntsr1 À/À PLCs and, to a lesser extent, in Ntsr2 À/À PLCs (Fig. 6a) . However, upon stimulation with ET-1 (4 mM), both Ntsr1 À/À -and Ntsr2 À/À -derived PMCs released serotonin to the same extent as did PMCs from congenic wild-type mice, indicating that a NT receptor deficiency does not impair PMC degranulation in response to an agonist other than NT ( Supplementary Fig. 7a online) . These results suggest that Ntsr1 and, to a lesser extent, Ntsr2 can contribute to NT degradation by PLCs. However, we found that mouse MCs expressed Ntsr1, as was reported for rat PMCs 26,37 , but not Ntsr2 (Supplementary Fig. 7b ). This result suggests that Ntsr2 expression by PLCs other than MCs can influence NT degradation, either directly and/or through effects on additional cell types.
Intraperitoneal injection of NT resulted in significantly lower MAP in Ntsr1 À/À BMCMCs-Kit W/W-v mice than in Ntsr1 +/+ BMCMCsKit W/W-v mice (P o 0.0001; Fig. 6b ). However, MAP was not as low in NT-injected Ntsr1 À/À BMCMCs-Kit W/W-v mice as in NT-injected Kit W/W-v mice (P o 0.0001; Fig. 3a) . The amount of intraperitoneal NT was also significantly higher in Ntsr1 À/À BMCMCs-Kit W/W-v mice than in Ntsr1 +/+ BMCMCs-Kit W/W-v mice (P o 0.04; Fig. 6c ), but levels in NT-injected Ntsr1 À/À BMCMCs-Kit W/W-v mice were not as high as those in NT-injected Kit W/W-v mice (P o 0.05; Fig. 3b) . Finally, survival after CLP was significantly higher in Ntsr1 +/+ BMCMCs-Kit W/W-v mice than in Ntsr1 À/À BMCMCs-Kit W/W-v mice (23% versus 0%, respectively, P o 0.025; Fig. 6d ). The percentages of PMCs in the peritoneal cavity of Ntsr1 +/+ BMCMCs-Kit W/W-v or Ntsr1 À/À BMCMCs-Kit W/W-v mice were very similar (3.2 ± 0.4% or 3.8 ± 0.8% of total cells), as was the distribution of MCs in the mesentery of these mice ( Supplementary  Fig. 8 online) .
DISCUSSION
Given the large number of molecules that are thought to influence the pathogenesis of sepsis, it is remarkable that mouse survival after severe CLP is significantly enhanced by either the genetic deletion of NT or the pharmacological inhibition of this peptide. Our findings thus show a heretofore unknown contribution of NT to the mortality associated with this model of sepsis. Our findings also identify a previously unknown and important role for MCs, and MC-associated NLN, in regulating NT concentrations, and thus the extent of NT-associated pathology, in vivo. Although it has been reported that certain MC populations can degranulate in response to NT 25 and that some MC-derived proteases can degrade NT in vitro 22, 23 , the effects of MCs and their products on the degradation of NT in vivo has not previously been investigated. We found that significantly higher amounts of NT occur during CLP in the peritoneal cavity of MC-deficient Kit W/W-v mice than in Kit +/+ wild-type mice or MC-engrafted Kit W/W-v mice, indicating that MCs can regulate the amounts of endogenously generated NT in this sepsis model.
MCs also can significantly reduce NT-induced hypotension upon intraperitoneal injection of the peptide in vivo. In the past, NT-induced changes in blood pressure have been attributed to NT-induced release of serotonin or histamine from MCs, suggesting that the effect of NT on MCs actually contributes to the hypotension induced by this agent 38 . However, these assumptions had not been tested in MC-deficient mice. High-affinity NT receptors are expressed on vascular endothelial cells as well as on MCs, suggesting that endothelium-derived vasodilators such as prostacyclin, rather than MC-derived products, may contribute to the hypotensive effects of NT 39, 40 .
We found that MCs can express the NT-degrading enzyme NLN 34 , and that the active enzyme was present in both cytosol and membrane fractions of these cells. In vitro studies have shown that NLN also can degrade bradykinin and angiotensin-I, implicating NLN in the regulation of blood pressure 41 . Mouse MCs are known to express CPA (that is, mMC-CPA) 42 , an exopeptidase that preferentially cleaves C-terminal aliphatic amino acids 43 . Pharmacological evidence indicated that either mMC-CPA or NLN can contribute to NT degradation when MCs are activated to degranulate extensively in vitro. However, in vivo studies with Kit W/W-v mice containing adoptively transferred MC populations in which either mMC-CPA or NLN was knocked down using an shRNA-based approach indicated that MC-associated NLN is more important than MC-associated mMC-CPA in reducing NT-induced hypotension in this setting.
Evidence derived from two different in vivo models supports the conclusion that the expression of Ntsr1 by MCs contributes to their ability to enhance resistance to the adverse effects of NT. Ntsr1 expression by MCs was required for optimal MC-dependent reduction in amounts of NT in the peritoneal cavity after intraperitoneal injection of the peptide (Fig. 6c) and for optimal reduction of NT-induced hypotension (Fig. 6b) . However, the hypotensive effects of NT, and the levels of peritoneal NT, were greater in MC-deficient Kit W/W-v mice than in Kit W/W-v mice engrafted with Ntsr1 À/À BMCMCs. Together, these findings suggest that MCs can confer protection against the hypotensive effects of NT by both Ntsr1-dependent and Ntsr1-independent mechanisms.
In our second in vivo model, CLP, Kit W/W-v mice engrafted with Ntsr1 À/À BMCMCs showed significantly poorer survival than did 1,000 Ntsr1 +/+ BMCMC-engrafted Kit W/W-v mice (Fig. 6d) . This finding further strengthens the conclusion that optimal MC function in diminishing adverse effects of NT, either after NT injection or in CLP, requires MC expression of Ntsr1. In preliminary in vitro studies, we found that rhodamine-labeled NT binds to and is internalized by PMCs to a greater extent than by other PLCs, and that PMCs lacking either Ntsr1 or both Ntsr1 and Ntsr2 show impaired ability to bind and internalize rhodamine-NT ( Supplementary Fig. 9 online and data not shown). These findings suggest that one mechanism by which Ntsr1 may promote degradation of NT by MC-associated NLN is to facilitate the uptake of NT by MCs. The origin of the NT produced during CLP in mice remains to be identified. In addition, the relevance of our findings in mice to the roles of NT and MCs in septic shock in humans remains to be assessed. In a pilot study, plasma concentrations of NT were elevated to levels similar to those in mice with severe CLP in people admitted to the intensive care unit with septic shock (median: 224 fmol/ml (range: 65-1,715 fmol/ml, n ¼ 17) versus 30 fmol/ml (range: 13.8-180 fmol/ml, n ¼ 14) in healthy controls, P o 0.0001; see Supplementary Table 1 online for the subjects' clinical characteristics). Notably, plasma concentrations of NT were similarly elevated in subjects with cardiogenic shock (median: 309 fmol/ml (range: 10-2,176 fmol/ml, n ¼ 6), P o 0.04 versus values for healthy control subjects; Supplementary Table 1) . These data raise the possibility that NT might contribute to hypotension in people with either septic or cardiogenic shock.
The role of human MCs in regulating NT abundance is not yet clear. It has been reported that plasma levels of the MC protease tryptase are not elevated in humans with sepsis 44 . Moreover, unlike in murine rodents, few MCs can be recovered in peritoneal lavage fluid in humans 45 . However, humans do have MCs within the mesentery and in the mucosa, submucosa and muscularis propria of the gastrointestinal tract 46, 47 . Moreover, human umbilical cord blood-derived MCs express mRNA for NLN, express Ntsr1 protein and, upon activation by a calcium ionophore, can degrade NT in vitro ( Supplementary Fig. 10 online) . In addition, our evidence in mice suggests that at least certain populations of MCs can reduce levels of NT in vitro or in vivo under conditions in which such MCs do not undergo extensive degranulation. Accordingly, the lack of elevated levels of plasma tryptase during human sepsis, which indicates the probable absence of extensive and ongoing MC degranulation in this setting, does not rule out a role for MCs in regulating NT abundance during sepsis in humans. Establishing the extent to which NT concentration is regulated by MCs during septic shock in humans may be difficult, as humans genetically deficient for MCs have not been reported. Nevertheless, our studies in mice raise the possibility that inhibiting pathological actions of NT may confer benefit in humans with this highly lethal disorder and may even be beneficial in subjects with cardiogenic shock.
METHODS
Chemicals and reagents. We purchased neurotensin (1-13) (Bachem Peninsula Labs), endothelin-1, A23187 and chymostatin (Sigma), potato carboxypeptidase inhibitor (Calbiochem) and Pro-Ile (Bachem Peninsula Labs) from the manufacturers. -deficient (Ntsr2 À/À ) mice were all on the C57BL/6J background except for the C57BL/6-Ntsr1 À/À mice (for which we used littermate C57BL/6-Ntsr1 +/+ mice as controls); we bred and maintained these mice at the Stanford University Research Animal Facility. Unless specified otherwise, we used 12-week-old female mice for experiments. We conducted all animal care and experimentation in accord with current US National Institutes of Health guidelines and with the approval of the Stanford University Institutional Animal Care and Use Committee.
Cecal ligation and puncture (CLP). We performed CLP as described 20 . Briefly, we anesthetized mice deeply by intramuscular injection of 100 mg/kg ketamine and 20 mg/kg xylazine. We exposed the cecum by a 1-2 cm midline incision on the anterior abdomen and subjected it to ligation of its distal portion and a single needle puncture of the ligated segment. For severe CLP, we ligated the distal one-half or two-thirds of the cecum (in mice on the C57BL/6 or (WB x C57BL/6)F 1 background, respectively) and made a single puncture with a 20-gauge needle; for moderate CLP (in wild-type mice on the C57BL/6 or (WB Â C57BL/6)F 1 background), we ligated the distal one-half of the cecum and made a single puncture with a 22-gauge needle. We developed protocols for eliciting severe or moderate CLP so that, on each strain background, 450% or 20-50% of the wild-type mice succumbed within 4 d after CLP. We then replaced the cecum into the abdomen, administered 1 ml sterile saline (pyrogen-free 0.9% NaCl) into the peritoneal cavity, and closed the incision using 9 mm steel wound clips. We observed mice for mortality at least four times daily. Mice that were clearly moribund were killed by CO 2 inhalation.
Mean arterial blood pressure (MAP) measurements. We anesthetized mice with 2% isoflurane. We exposed the carotid artery through a midline incision in the upper thorax and then cannulated it with a pressure transduction catheter connected to a computerized pressure monitor (Powerlab) to record blood pressure. We calibrated the transduction system using a sphygmomanometer. After we reduced the level of isoflurane to 1%, we allowed the blood pressure and respiratory rate of the mouse to stabilize for several minutes. We then administered 300 ml saline intraperitoneally and recorded MAP at baseline. There were no significant differences among the various groups of mice tested in single experiments in baseline measurements of MAP. Three minutes after saline administration, we injected NT intraperitoneally (6 nmol/300 ml saline) and recorded blood pressure for 30 min. Data are presented as changes in MAP after NT administration in relation to baseline (''time 0'').
MC engraftment of Kit W/W-v mice. We repaired some Kit W/W-v mice (female, 4-6-week-old) of their MC deficiency selectively and locally by intraperitoneal injection of growth factor-dependent congenic Kit +/+ BMCMCs. Briefly, we maintained femoral bone marrow cells from Kit +/+ mice in vitro for B4 weeks in IL-3-containing medium until MCs represented 495% of the total cells according to staining with May-Grünwald-Giemsa. We injected 2.0 Â 10 6 BMCMCs in 200 ml PBS intraperitoneally (with a 26-gauge needle) and used the mice for experiments, together with gender-and age-matched MC-deficient Kit W/W-v mice, 4-6 weeks after adoptive transfer of BMCMCs. Other Kit W/W-v mice received, 4-6 weeks before injection of NT intraperitoneally or CLP, 2.0 Â 10 6 BMCMCs generated from either Ntsr1-deficient mice (Ntsr1 À/À ) or the congenic normal mice (Ntsr1 +/+ ). Other Kit W/W-v mice received, 4 weeks before intraperitoneal injection of NT, injections of 1.0 Â 10 6 BMCMCs that had been transduced with NLN-or mMC-CPA-targeting shRNA or with empty vector.
Additional methods. Lentiviral vector production, preparation of NLN shRNA-or mMC-CPA shRNA-containing MCs, RT-PCR, membrane preparations, western blot analysis, CPA enzymatic activity assay, b-hexosaminidase and serotonin release, NT and ET-1 measurements, evaluation of MCs in the peritoneal cavity and mesenteric windows and human umbilical cord bloodderived MC generation are described in the Supplementary Methods online.
Statistical analysis. We used analysis of variance (ANOVA) for repeated measures to assess differences in the changes in mean arterial blood pressure. We assessed differences in the survival rates after CLP using the MantelHaenszel log-rank test and the extent of MC degranulation by the Chi-square test. All other data were analyzed for statistical significance with the unpaired two-tailed Student's t-test or Mann Whitney U-test. P o 0.05 is considered statistically significant. Unless otherwise specified, all data are presented as mean ± s.e.m.
Note: Supplementary information is available on the Nature Medicine website.
